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Abstract 
 
Purpose: To determine the availability of relevant and objective outcome measures concerning 
Complex Regional Pain Syndrome Type I (CRPS I) for Rehabilitation Medicine. 
Method: Outcome measures were classified according to the International Classification of 
Impairments, Disabilities and Handicaps. For each outcome measure a description of concept, 
operationalisation into variables and instrument was given. We performed a PUBMED 
MEDLINE search (1980-1998) using the following keywords: complex regional pain syndrome, 
reflex sympathetic dystrophy, impairment, disability, handicap, (long-term) outcome and 
effect/efficacy. 
Results: Most outcome measures were concentrated on impairments, whereas measures at 
the level of disabilities and handicaps, the most relevant levels for Rehabilitation Medicine, were 
mentioned in very few studies. Objective outcome measures were merely found at the level of 
impairment.  
Conclusion: The results indicate a need for the development of relevant outcome measures at 
the level of disabilities and handicaps that can objectively measure treatment efficacy for CRPS 
I. 
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Introduction 
 
Complex Regional Pain Syndrome Type I (CRPS I; also known as Reflex Sympathetic 
Dystrophy) is a poorly understood and not well defined symptom complex comprising a 
combination of sensory, trophic, autonomic and motor impairments 1,2. The syndrome usually 
follows surgery or trauma, and is generally expressed in the extremities. In addition to the 
impairments, CRPS I can lead to serious disabilities in performing activities of daily life and 
handicap 3,4. In the acute phase of CRPS I, pain in particular may constitute a major cause of 
disability and/or handicap, whereas during the later stages CRPS I-associated motor 
impairments, together with pain, are thought to bring about disabilities and/or handicaps 1,5,6. 
The complex entity of CRPS I has often been investigated, leading, however, to confusing and 
conflicting results and theories about the aetiology and pathophysiology 7. As the disease is not 
yet understood, plus the fact that each speciality has its own discipline-specific approach, a 
wide variety of treatments (more than 50) is found in literature 8. As a consequence, numerous 
measures to determine treatment outcome have been described.  
In the present paper, the numerous measures that are used to determine treatment outcome in 
CRPS I research and clinical practice will be classified. So far, one of the difficulties in 
interpreting reports on treatment efficacy in CRPS I, has been the (objective) quantification of 
patient findings and the lack of uniform measurement of treatment outcome 9,10. Classification 
of outcome measures may not only be a useful tool to indicate the extent of the (obvious) 
inconsistency in defining treatment outcome in CRPS I research. The main aim of classifying 
outcome measures in the present paper is to determine whether relevant and objective outcome 
measures for Rehabilitation Medicine are available. It is clear that objective outcome measures 
are preferable to subjective outcome measures; the latter are more likely to endanger reliability 
and validity of measurements. As for the relevance of outcome measures: outcome measures 
are considered most relevant for Rehabilitation Medicine when they concern the goal of 
Rehabilitation, that is regaining and/or maintaining of functionality by decreasing the 
consequences of a disease 11,12. Outcome measures concerning impairments are considered 
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less relevant for Rehabilitation Medicine, especially since the relation between the 
consequences of a disease is often found to be rather ambiguous 13-15. 
The International Classification of Impairments, Disabilities and Handicaps (ICIDH) 16 is an 
often-used classification, in which three hierarchical levels of the consequences of a disease on 
everyday life of patients are distinguished. Outcome measures on the level of impairments, 
disabilities and handicaps concern the consequences of diseases at the level of the body, the 
person and the person as a social being, respectively. As for CRPS I, the consequences at the 
ICIDH level of impairments can be categorised into sensory impairments (e.g. neuropathic pain, 
allodynia, hyperalgesia, hypesthesia, anaesthesia, dysesthesia, hyperpathia), autonomic 
impairments (e.g. oedema, hyperhydrosis, skin colour change, change of temperature), trophic 
impairments (e.g. atrophy of skin, nails, muscles and bone), and motor impairments (e.g. 
dystonia, weakness, spasms, tremor, difficulty initiating movement, increased tone and reflexes, 
and increase of complaints after exercise) 8. Disabilities associated with CRPS I are those 
directly related to the involved extremity (e.g. problems with getting dressed with upper 
extremity CRPS I or climbing stairs with lower extremity CRPS I) and general disabilities in daily 
functioning (e.g. slow performance of activities of daily living). Handicaps associated with CRPS 
I concern limitations in social functioning (e.g. alienation) and problems with role fulfilment (e.g. 
a grandmother with CRPS I cannot play with her grandchild), as a consequence of pain, other 
impairments or disabilities 17. From this list of consequences it becomes clear that CRPS I 
encompasses all three levels of the consequences of a disease as described in the ICIDH). 
Although some discussion continues about the sometimes unclear distinction between the 
theoretical levels of the ICIDH 18,19, we consider the ICIDH framework useful to classify 
outcome measures in order to make a statement on availability of relevant and objective 
outcome measures for Rehabilitation Medicine.  
 
Method and data sources 
 
To obtain data, a PUBMED MEDLINE search (1980-1998) was performed using ‘complex 
regional pain syndrome’, ‘reflex sympathetic dystrophy’, ‘impairment’, ‘disability’, ‘handicap’, 
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‘(long term) outcome’ and ‘effect’ as keywords. The initial idea of only using randomised clinical 
trial studies and quasi-experimental studies was not feasible given the relatively small number 
of studies performed up till now. Therefore, non-experimental and transversal studies with 
descriptions of one or more outcome measures were also included. Only journal articles in the 
English or Dutch languages were used. Publications without MEDLINE abstract and studies with 
less than 8 subjects were excluded. To provide insight in the kind of research that is performed 
concerning CRPS I, we studied some characteristics of the publications used for classification of 
outcome measures. 
To determine the success of treatment in a reliable and valid manner, well-defined and 
methodologically sound outcome measures are of major importance 20-22. In general, an 
outcome measure can be considered methodologically sound when the theoretical definition of 
the outcome measure (at the conceptual level) is clearly operationalised into one or more 
variables 21. Moreover, an appropriate instrument to assign a value to variables has to be 
chosen 21. In this study, we represented each outcome measure in a scheme, in which the 
concept to be measured, the operationalisation of this concept into variable(s), and the 
instrument to assign a value to the variables were described. It was not our aim to take reliability 
and validity of measurements with different instruments into account. Each outcome measure 
was classified according to the three levels of a consequence of a disease (impairment, 
disability and handicap). The earlier described categorisation of impairments 8 was also applied 
in the tables. 
Each publication was analysed to find information about concept, operationalisation of concept 
into variable(s), instrument and level of the ICIDH-classification of the described outcome 
measures. Almost identical descriptions of concept, operationalisation and/or instrument of two 
or more outcome measures in different publications were represented as one outcome measure 
to limit the size of the tables. In case the concepts of outcome measures in different publications 
were similar, but different operationalisations and/or instruments were described, the outcome 
measures were shown separately 
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Results 
 
To provide insight in the kind of research that is performed concerning CRPS I, some 
characteristics of the studies were described (table 1). In addition to information about the first 
author and year of publication, studies were categorised as either transversal or longitudinal 
depending on the number of measurements. Transversal studies were categorised as either 
retrospective or prospective depending on whether measurements are done with data that 
already existed before defining the research questions or yet to be acquired data. Longitudinal 
studies were categorised as either experimental or non-experimental depending on whether the 
researcher actively intervenes in the research process or not. Specification of the type of 
treatment and research field, based on the first author, were presented, as well.  
 
Insert table 1 about here 
 
Outcome measure at the level of impairment 
Sensory impairment 
A variety of outcome measures at the ICIDH level of sensory impairments were found (table 2). 
However, only few of the earlier described familiar CRPS I-associated sensory impairments 
8,23 were used as concepts of outcome measures. It is clear that the concept of pain is most 
frequently used in CRPS I research and practice. 
 
Insert table 2 about here 
 
Although there was general acceptance of pain as the main concept, operationalisation of this 
concept differed considerably (table 2). In some publications, pain was operationalised by 
simply describing the type 24 or location 9,10 of pain. Other operationalisations of the concept 
of pain were focussed on the level of pain, indicated by using the terms degree 25, score 26, 
intensity 10,15,27,28 or severity 27-29 of pain. Changes in the level of pain were indicated by 
usage of the terms decrease 30, change 31-33, relief 25,34,35 or reduction 32,36. These 
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differences in operationalisation were not related to the design of the study. From a 
methodological perspective, it may be expected that pain was operationalised as changes in 
pain level in longitudinal studies and as pain level in transversal studies, which was, however, 
not consistently done. In general, operationalising pain was considered obvious and was not 
extensively described. In addition to pain, tenderness was the only other sensory impairment 
that was used as an outcome measure concept in more than one publication. As for the 
instruments to measure pain, it appeared that pain was mainly measured by scales and 
questionnaires and virtually no objective instruments were used.  
 
Autonomic impairments 
Autonomic impairments of CRPS I patients can be categorised as changes in temperature, 
changes in skin colour, changes in volume and changes in sweat secretion 8. These four 
autonomic impairments associated with CRPS I have all been used as outcome measure 
concepts (table 3): a large variety of ‘autonomic’ outcome measures were found. Some authors 
consider autonomic impairments as a cluster of signs or symptoms, which was represented by 
conceptual umbrella terms, such as ‘vasomotor instability’ 29,37-39 or ‘vasomotor changes’ 32. 
Most authors, however, did not use such umbrella terms. For clarity, the initial concepts of 
tumour 31, oedema 9,15,26,40 and swelling 10,25,27,29,37-39,41,42 were grouped as volume. 
Operationalisations shown in table 3 are original operationalisations and were not renamed. Of 
the autonomic impairments, (changes in) volume was clearly most often used as concept of 
outcome measures.  
 
Insert table 3 about here 
Operationalisations of the autonomic impairment concepts, as well as the instruments to 
measure autonomic impairments were not uniform. Part of the outcome measure 
operationalisations were expressed as a ratio of affected and unaffected side, whereas the 
other part only took the affected side into account. The three outcome measures at the bottom 
of table 3 were separated from the other outcome measures. This was done because they could 
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either be considered as an outcome measure with a general operationalisation of more than 
one of the four autonomic impairments 37-39,42,43, or because none of the four autonomic 
symptoms were mentioned specifically in the text 44. 
 
Trophic impairments 
Only few outcome measures at the level of trophic impairments were found (table 4). Nearly all 
of these outcome measures were used by highly specialised disciplines, such as Nuclear 
Medicine and Human Metabolism & Clinical Biochemistry. 
 
Insert table 4 about here 
 
Motor impairments 
A large number of ‘motor’ outcome measures at the ICIDH level of impairments were found 
(table 5). Lack of unity in defining outcome measures was very obvious with motor impairments: 
concepts, operationalisation as well as instruments differed enormously. Studies mainly 
focussed on operationalisation and instruments mentioning the concept to be measured. 
Information about concepts had to be extracted from all sections of the publications, which 
made some interpretation unavoidable. In several publications 10,15,38,41,42 information about 
concepts could not be found.  
 
Insert table 5 about here 
 
Range of Motion (ROM) was the most frequently adopted operationalisation of motor 
impairment outcome measures. Measurement of active or passive ROM was not always 
specified. Moreover, ROM was not consistently measured in the same joints of upper or lower 
extremity. In one study 29 the instrument to determine ROM was not specifically mentioned, 
which forces one to make assumptions when trying to classify the different outcome measures.  
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Outcome measures at the level of disability and handicap 
 
Relatively few studies expressed the outcome of a CRPS I treatment in terms of disability and/or 
handicap (table 6). Therefore, we decided to describe the outcome measures of these two 
levels together. Concepts as well as operationalisations of outcome measures were described 
in very different ways, although the majority of outcome measure concepts at the level of 
disabilities were related to occupation. Instruments to assess ‘disability’ and ‘handicap’ were 
scales and questionnaires.  
 
Insert table 6 about here 
 
Operationalisation into activity level categories in ordinal scales was not always consistent and 
scales or interviews sometimes contained items with different levels of abstraction 32,42 
including some items at the level of impairments, which made interpretation of treatment 
outcome difficult. Some instruments (e.g. RAND-36 Questionnaire) contain items at both the 
level of disabilities and at the level of handicaps 45. Topics of the structured interview were not 
always reported 9.  
 
Discussion and conclusion 
 
Level of impairments 
Sensory impairments 
The almost unanimous choice of pain as the main ‘sensory’ outcome measure concept may be 
attributed to the fact that pain is often described as the most unpleasant feature of CRPS I for 
the majority of patients 1,5,8,46,47. The large variability of other sensory impairments between 
patients and the lack of valid and reliable instruments may also play a role in this choice.  
An important aspect in the evaluation of pain that was not taken into account in any of the 
studies is that, in CRPS I, acute pain in early stages of the disease most likely changes into 
chronic pain in later stages. Acute and chronic pain can be considered as different clinical 
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entities 48, which may not involve the same dimensions 49,50. Therefore, one has to carefully 
consider the moments of measurement and the choice for a specific instrument to determine 
long-term pain evaluation in CRPS I; not all instruments are designed to reflect these different 
dimensions of acute and chronic pain.  
To clearly classify the numerous outcome measures, we tried to fit each outcome measure in 
the scheme of concept, operationalisation and instrument. With respect to the operationalisation 
of the outcome measure concept of pain, this gave rise to some difficulties because authors 
usually failed to present an explicit operationalisation. It appeared that the majority of authors 
consider pain as a clear-cut concept, thus making some interpretation unavoidable. We realise 
that one may ask whether ‘level of pain’ and ‘changes in level of pain’ are actually 
operationalisations of pain, but in these cases thorough analysis of the publications failed to 
provide more detailed information.  
Pain clearly is a very complex and diverse concept that can be interpreted or classified in 
several ways 51. In one publication, pain was operationalised as mechanical allodynia and 
spontaneous deep pain 32. These operationalisations, however, are both discrete sensory 
impairments in the framework of the ICIDH. In contrast to this framework, in which pain is 
considered as one of the sensory impairments in CRPS I, pain can also be considered as a 
separate entity 10,52, that can be classified into several levels of abstraction: nociception, pain, 
suffering and pain behaviour 51,53. Because pain is often described as the most unpleasant 
feature of CRPS I and especially since it is the impairment that particularly leads to disability 
(which can be described in terms of pain behaviour), one may consider this latter classification 
also applicable to classify the CRPS I outcome measures. Although we acknowledge that the 
ICIDH is not ideal to classify the concept of pain, there are two reasons why we think the ICIDH 
is the most suitable framework to classify the numerous outcome measures. First, pain clearly is 
not the only consequence of CRPS I; using this other classification would not do justice to the 
other impairments that are found in CRPS I. Second, pain is not present in all CRPS I patients 
54,55; about ten percent of the patients do not have pain, which makes the alternative 
classification not applicable to determine outcome for this part of the patient group. 
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Pain and other sensory impairments were usually measured by scales and questionnaires. A 
major disadvantage of these instruments is their subjective character 56,57. Another problem 
with measuring pain in CRPS I is that pain of individual patients can change often during the 
day and the pain level between patients can also vary widely 58. The instruments to measure 
pain are not capable of detecting variation in pain level throughout the day. A possibility to 
overcome these problems is to evaluate ‘pain behaviour’ in addition to pain as a sensory 
impairment 51,53,59, especially because latest technological developments provide possibilities 
to objectively measure pain behaviour 60. For Rehabilitation Medicine, measuring the concept 
pain behaviour operationalised as (changes in) the activity pattern is more relevant than 
measuring pain alone because pain behaviour is an outcome measure at the ICIDH level of 
disability and not at the level of impairment. 
 
Autonomic impairments 
It is clear that the number of ‘autonomic’ outcome measures by far exceeds the number of other 
outcome measures at the level of impairments, with the exception of pain. The popularity of 
‘autonomic’ outcome measures together with ‘sensory’ outcome measures may be related to the 
current ideas concerning aetiology and pathophysiology of CRPS I. Sensory and autonomic 
impairments represent the most important features of an inflammatory reaction (dolor, calor, 
rubor and tumor) which are thought to play a role in the acute phase of CRPS I 55,61. The 
acute phase is the focus of the majority of CRPS I studies. However, the greater part of CRPS I 
patients in Rehabilitation Medicine in the Netherlands are already in the later stages of the 
disease, which makes autonomic outcome measures less relevant for determining treatment 
efficacy. 
Autonomic outcome measures are frequently measured by subjective purpose-formulated 
scales or questionnaires, although objective instruments are available 15,27,32,34,38,39,62. 
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Trophic impairments 
Trophic impairments are not often used as outcome measures. This may be because these 
impairments are only found in a minority of CRPS I patients 43,55 which makes ‘trophic’ 
outcome measures a less logical choice. Even though objective measurement is trophic 
impairments is possible, a major disadvantage is that instruments are usually costly and not 
always available. Moreover, objective measurement requires trained personnel. Trophic 
impairments are generally measured for diagnosis of CRPS I and not to determine the effect of 
a treatment, although some authors have investigated the possibilities of using them as 
outcome measures 63. It was concluded that the bone scan could be part of an algorithm rather 
than a discrete outcome measure. Trophic impairments are closely related to autonomic 
impairment; changes in the nutritional state are one of the consequences of changes in local 
blood flow, which, for some researchers, may make use of these measures redundant.  
 
Motor impairments 
Whether active Range of Motion (AROM) or passive range of motion (PROM) was measured 
was not always clear. This is a very important issue, however, because measuring PROM is 
assumed to be not appropriate for patients with CRPS I since the pain threshold is generally 
reached quickly 58. In addition, ROM measurements in CRPS I patients are subject to 
considerable variation 64, which may have an impact on the objectivity and reliability of 
measurements. This is also true for grip strength: it was found that for objective medical reports 
on hand muscle strength, it is recommendable to measure three times in more than one session 
and, if possible, by more than one person 65. In the studies that used grip strength as an 
outcome measure, only few actually used a (potentially) objective method 15,38,39,41,42. In 
only one of these studies 15 was information presented about repeated measurement. 
Even though motor impairments form a well-known aspect of CRPS I, epidemiological data on 
this matter are still scarce 6. Whether this is a matter of lack of interest or lack of objective, 
reliable and valid instruments is not clear. However, it may be that researchers usually focus on 
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the early stages of CRPS I, whereas motor impairments become more obvious in the later 
stages. 
 
Sum scores 
In order to indicate the ‘overall’ condition of patients, in several studies, scores were assigned to 
a number of outcome measures and added to sum scores called Reflex Sympathetic Dystrophy-
score 15,40, also Reflex Sympathetic Dystrophy-score 25,31 or Shoulder Hand Syndrome-
score 66. Reflex Sympathetic Dystrophy (RSD) and Shoulder Hand Syndrome (SHS) are two of 
the numerous names that are used to describe the disease. In the present study, we decided to 
use the term CRPS I because this is the term the International Association for the Study of Pain 
recently agreed upon 67. Sum scores were made up of a varying numbers of outcome 
measures that usually had different relative contributions to the total score. This may be related 
to the discipline involved (e.g. ROM is more important to a rehabilitation specialist or an 
orthopaedist, whereas changes in temperature may be more relevant for an anaesthesiologist). 
In these 5 sum scores, pain was generally considered (one of) the most important concept(s) of 
outcome measures. In the selection of other outcome measures, however, little consistency in 
order of importance was found which makes interpretation of treatment outcome and 
comparison of different studies very complicated. An additional sum score, the Impairment level 
Sum Score (ISS)58, was published after the initial MEDLINE-search. In this weighted sum 
score, pain is also the most important outcome measure concept. 
Since the consequences of CRPS I encompass all three levels of the ICIDH, assessing 
treatment outcome by sum scores of different outcome measures at different ICIDH levels can 
be considered as a logical strategy. However, with the exception of the variable VAS-ADL in 
one of the RSD scores 15,40 and the affective and evaluative variables of the McGill Pain 
Questionnaire in the Impairment level Sum Score 58, all of the variables in these scores were 
exclusively on the level of impairments. Variability among patients regarding the functional 
impact of various impairments was reported as a reason to solely focus on the level of 
impairments 58. 
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Level of Disabilities and Handicaps 
The small number of ‘disability’ and ‘handicap’ outcome measures that were found, were 
assessed by means of scales and questionnaires; no objective instruments were used. About 
half of the outcome measures at the level of disability and/or handicap were employed by 
researchers in the field of Rehabilitation (table 1). Apparently, outcome measures at these 
levels are also considered relevant by researchers in other research fields. With the exception 
of two studies 27,68, all studies in which outcome measures at the ICIDH level of disabilities 
and/or handicaps in CRPS I research were used are written in the last few years. This may also 
be related to increasing general recognition that the evaluation of treatments should include 
assessment of a broad set of outcome measures that are important to patients, especially 
functionality (level of disabilities), role performance (level of handicaps) and quality of life 69-72.  
Clearly, assessing treatment outcome at the level of disabilities and/or handicaps is difficult: 
particularly when it comes to objective outcome measures. In one study 73, it was mentioned 
that the outcome measures ‘increase in hours of sleep’ and ‘increase in physical activity’ were 
taken into account. However, the authors failed to report on these outcome measures, which 
may also indicate that objectively assessing outcome at these two levels is considered relevant 
but difficult. 
 
General discussion and conclusion 
 
The aim of the present paper was to determine the availability of relevant and objective outcome 
measures concerning CRPS I for Rehabilitation Medicine. It appears that there clearly is a gap 
in the availability of these measures. Gaps in availability of appropriate outcome measures may 
be the starting point for the development of new instruments that are capable of objective 
measurement at the higher levels of the ICIDH. This does not implicate that we consider 
outcome measures at the level of impairment irrelevant for Rehabilitation Medicine. These 
outcome measures would be very relevant if there were an unambiguous relationship between 
impairments and changes in functionality; no clear evidence for such a relation in CRPS I has 
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yet been found. Studies investigating whether patients benefit from treatment in terms of 
improvement of functional health require disability and/or handicap measures 74. Insight into a 
patient’s disabilities and handicaps is also important for the choice of treatment. 
For this overview of outcome measures used in CRPS I research and clinical practice, 30 
publications were analysed. It was not our intention to be fully exhaustive: we omitted studies 
with small patient numbers because these studies usually report on preliminary results of 
employment of ‘new’ outcome measures. Classifying these outcome measures may result in an 
overview of one-time employed outcome measures, which was not the objective of this study. In 
the data selection we did not perform cross-referencing because we think that the outcome 
measures currently classified are representative for the outcome measures applied in CRPS I 
research in general. In our opinion, cross-referencing would not have added many other 
outcome measures; it would merely result in a larger number of references in the Reference No. 
columns in tables 2-6. Again, it was not our intention to be fully exhaustive. 
The clinical picture of CRPS I has been described by authors from different clinical disciplines, 
such as anaesthesiologists, hand surgeons, orthopaedists, psychiatrists, and rheumatologists 7. 
These different disciplines have not unexpectedly emphasised different signs, symptoms, 
diagnostic criteria, treatments and outcome measures, which may be a reason for some of the 
difficulties in reviewing the literature on CRPS I. The fact that little controlled research on CRPS 
I is done from the perspective of Rehabilitation 75 may have contributed to the lack of relevant 
outcome measures at the level of disabilities and/or handicaps. On the other hand, all 
disciplines should attempt to determine whether patients benefit from treatment in terms of 
improvement of functional health. 
Due to the lack of consensus about pathogenesis, current treatments do not always have a 
rational basis 8; this may have had an impact on the selection of outcome measures for 
determining treatment efficacy. Ideally, the selection of certain outcome measures depends on 
the questions to be answered in different studies 74; namely, whether the treatment has a 
biological effect or a clinical effect. Research and treatment of CRPS I may still be in an early 
experimental phase, despite the amount of research that has already been performed. For 
studies on pathogenesis, impairment outcome measures probably are the best choice. Clinical 
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decision making can be improved by measuring at the level of disability, however, because 
these measures provide important and patient relevant information on whether a treatment 
improves the patient’s functional health. Moreover, expressing outcome in terms of disabilities 
and handicaps, in addition to impairments, facilitates communication between disciplines and 
between specialists and patients.  
 
In summary, classification of outcome measures in CRPS I research according to the 
hierarchical levels of the ICIDH shows that the majority of outcome measures describe 
treatment success at the level of impairment. Little consistency was found in concepts, 
operationalisation of these concepts into variables and the instruments used. Outcome 
measures at the levels of disability and handicap, the most relevant levels for Rehabilitation 
Medicine, were mentioned in only very few studies. Objective outcome measures were merely 
found at the level of impairment. The shortage of relevant and objective outcome measures can 
not be due to lack of interest in such outcome measures or in CRPS I. This finding calls for 
development of relevant outcome measures that can objectively measure treatment efficacy at 
the level of disabilities and handicaps. Recent developments in the field of ambulatory activity 
monitoring 76,77 seem to offer good perspectives.  
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Captions of tables 
 
Table 1: Overview of several aspects of the publications studied. 
 
Table 2: Outcome measures used in CRPS I research to measure sensory impairments. 
Insufficient descriptive detail in publications is represented by a question mark. 
 
Table 3: Outcome measures used in CRPS I research to measure autonomic impairments. 
Insufficient descriptive detail in publications is represented by a question mark. The bottom 
three rows represent outcome measures that do not fit into the categories of Kurvers (1997). 
 
Table 4: Outcome measures used in CRPS I research to measure trophic impairments. 
Insufficient descriptive detail in publications is represented by a question mark. 
 
Table 5: Outcome measures used in CRPS I research to measure motor impairments. 
Insufficient descriptive detail about concepts in publications is represented by a question mark. 
 
Table 6: Outcome measures used in CRPS I research to measure disabilities and handicaps. 
Insufficient descriptive detail in publications is represented by a question mark. 
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(table 1) 
      
      
Author(s) (+Ref. no.) Year Design^ Subjects (n) Type of treatment Research field 
Atkins et al.39 1990 tran., pros.  60 no treatment  Orthopaedic Surgery 
Bickerstaff et al.41 1991 long., exp. 20 (+20 control) nasal calcitonine (Sandoz Basle) Hum. Metabolism & Clin.Biochemistry 
Bickerstaff et al.42 1994 long., non-exp. 274 no treatment  Hum. Metabolism & Clin.Biochemistry 
Braus et al.66 1994 long., exp. 36 oral corticosteroids (methyl prednisolone) + daily physical therapy Neuropathology 
Cortet et al.30 1997 long., exp. 23 intravenous 2nd generation biphosphonate pamidronate (APD) Rheumatology 
Davidoff et al.10 1988 long., exp. 17 exercise program (8 weeks) + corticosteroids or sympathetic blockade Rehabilitation Medicine 
Field et al.37 1992 long., exp. 55  intravenous regional anaesthesia + cast immobilisation (4 weeks) Orthopaedics 
Field et al.38 1993 long., exp. 17 serial regional intravenous guanethidine blockade Orthopaedics 
Geertzen et al.40 1994 long., exp. 26 regional intravenous ismelin blocks (n=13) + radical scavenger DMSO (n=13) Rehabilitation Medicine 
Geertzen et al.15,45 1998 tran., retro.+ pros. 65 no particular treatment (follow-up after various treatments)  Rehabilitation Medicine 
Gobelet et al.9 1991 long., exp. 33 (+33 control) physical therapy combined with calcitonine  Rehabilitation Medicine 
Hamamci et al.26 1996 long., exp. 24 (+16 control) intramuscular salmon calcitonine treatment Rehabilitation Medicine 
Hassenbusch et al.32 1996 long., exp. 30 peripheral nerve stimulation Neurosurgery 
Hord et al.34 1992 long., exp. 12 intravenous regional bretylium and lidocaine Anaesthesiology + Orthopaedics 
Kaplan et al.33 1996 long., exp. 53 intravenous regional guanethidine Bier block  Anaesthesiology + Pain Management 
Kozin et al.78 1981 tran., pros. 48 (+16 control) no particular treatment Radiology 
Langendijk et al.25 1993 long., exp. 37 dimethylsulfoxide DMSO (50%) in a fatty cream Pharmacy 
Mailis et al.62 1997 long., exp. 15 (+21 control) intravenous administration of sodyum amytal, a medium action barbiturate Pain Investigation Unit 
Muramatsu et al.29 1998 long., exp. 17 Movelat cream manipulation (MIRA) therapy and regional anesthesia Orthopaedic Surgery 
*Poplawski et al.27 1983 tran., retro.+ pros. 62 no particular treatment  Orthopaedics 
*Poplawski et al.27 1983 long., exp. 27 regional intravenous block (+corticosteroids) followed by physical therapy Orthopaedics 
Ramamurthy et al.28 1995 long., exp. 30 (+30 control) intravenous regional block with guanethidine Anaesthesiology 
Rauck et al.36 1993 long., exp. 26 epidural clonidine  Anaesthesiology 
Robaina et al.73 1989 long., exp. 35 transcutaneous electrical nerve stimulation + spinal cord stimulation (n=6 of 35) Neurosurgery + Anaesthesiology 
Schwartzman et al.24 1997 tran., retro. 29 transthoracic or lumbar sympathectomy  Neurology 
Subbarao et al.68 1981 tran., retro.+ pros. 77 no particular treatment (follow-up after various treatments)  Rehabilitation Medicine 
Tu et al.44 1994 tran., pros. 8 surgical sympathectomy Radiology 
Vande Streek et al.63 1998 tran., pros. ? no treatment Nuclear Medicine 
Veldman et al.35 1995 long., exp. 71 injection of bupivacaine + methylprednisolone for RSD shoulder complaints Surgery 
Zuurmond et al.31 1996 long., exp. 16 (+15 control) dimethylsulfoxide in a fatty cream Anaesthesiology 
^ long.= more than one measurement, tran.= one measurement, retro.= data already available, pros.= data yet to be aquired, exp.= active intervention, non-exp.= no active intervention 
* The study of Poplawski et al. consists of two parts with distinct designs that are shown separately.
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(table 2) 
    
    
Concept Operationalisation Instrument(s) Reference No. 
pain burning pain Visual Analogue Scale (VAS)  24 
pain change in level of diffuse pain Visual Analogue Scale (VAS)  31 
pain change in level of diffuse pain examination: pressure exerted over tendons 35 
pain change in level of mechanical allodynic + spontaneous pain Verbal Digital Scale (0-10) 32 
pain change in level of pain Verbal Digital Scale (0-10) 30 
pain change in level of pain Visual Analogue Scale (VAS)  25,30,34 
pain change in level of pain 4-point scale  33 
pain change in level of pain question(naire) or patient's estimate 32 
pain change in level of sensory, affective + miscellaneous pain McGill Pain Questionnaire (PRI ) 36 
pain level of pain Visual Analogue Scale (VAS)  10,26,36,40,47,73 
pain level of pain McGill Pain Questionnaire 28,73 
pain  level of pain 3,4 or 6-point scale 27,29,66 
pain presence or absence of pain question(naire) or patient's estimate 39,41,42 
pain joint pain (at rest or during movement) by palpation 4 or 5-point score  9,10 
pain affective, sensory + evaluative aspects pain McGill Pain Questionnaire (PRI+NWC) 10 
pain pain as part of general health RAND-36 Questionnaire 79 
hyperalgesia intensity of hyperalgesia 6-point scale 66 
tenderness  tenderness of wrist, MCP, PIP, DIP  investigation 26 
tenderness bony tenderness in response to load compared to other hand Dolorimeter ratio (kg/m2)  37-39,41,42 
? moving two-point discrimination volar tip thumb+index finger Disk Discriminator (mm)  79 
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(table 3) 
    
    
Concept Operationalisation Instrument(s) Reference No. 
skin temperature 
calor elevated skin temperature compared to other side dorsal side observer's hand + patient's estimate 25,31 
? bilateral skin temperature ? 28 
vasomotor instability abnormal temperature affected hand 2-point questionnaire 42 
calor 2-point temperature profile skin compared to other side ? 10 
vasomotor instability (7-point) temperature profile skin compared to other side portable thermography 32,38 
? skin temperature response (to electrical stimulation) thermometer 34,62 
skin colour 
discoloration difference in skin colour compared to other side 3-point scale 15,40 
rubor  difference in skin colour compared to other side observation/examination  25,31 
vasomotor tone changes change in skin colour compared to other side examination on 4-point scale 32 
vasomotor instability abnormal skin colour affected hand 2-point questionnaire 42 
volume 
volume diffuse edema observation/examination 31 
volume degree of oedema compared to other side observation 25 
vasomotor tone changes degree of swelling compared to other side observation 32 
volume degree or severity of oedema dorsal side throughout day 4-point scale 29 
autonomic problem degree or severity of distal oedema 4-point scale 66 
volume degree or severity of oedema 3 or 4 point scale (examination) 9,15,26,40 
volume volume hand compared to other side ratio water displacement (+ assessment) 10,37-39,41,42 
volume digital circumference compared to other side arthrocircameter or measuring tape 15,27,38,39 
volume skin thickness compared to other side skinfold calipers on dorsum hand (mm) 39 
perspiration 
vasomotor instability hyperhidrosis affected hand 2-point questionnaire 42  
? hyperhidrosis affected hand compared to other side observation 25 
? bilateral electrodermal activity from sweat glands electrical stimulation and macroelectrode recording 62 
 
vasomotor instability response to external factors/environmental changes questionnaire 37-39,42 
? assymmetrical  blood flow in extremities scintigraphy 43 
vasoconctrictor tone blood flow distal artery muscle affected side colour duplex Doppler ultrasound   44 
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(table 4) 
    
    
Concept Operationalisation Instrument(s) Reference No.
 
trophic changes degree of trophic changes examination, 4-point scale 32 
? abnormal hair or nail growth compared to other side observation  25 
skeletal changes trabecular bone evaluation radiographic scoring system 41 
skeletal changes cortical bone evaluation of metacarpals morphometry 41 
skeletal changes bone mineral density compared to other side Nuclear Data ND 1100 scanner 41 
dynamic boney changes periarticular bone uptake compared to other side Three-Phase-Bone-Scan (TPBS) 63 
osteoporosis demineralisation  radiography 43 
? increased periarticular activity compared to other side scintigraphy 43 
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(table 5) 
    
    
Concept Operationalisation Instrument(s) Reference No.
loss of motor function pinch grip, elbow flexion and shoulder abduction Motricity Index 26 
weakness grip strength compared to other side hand held strength gauge 41,42 
joint function  grip strength compared to other side sphygmomanometer 39 
? grip strength compared to other side dynamometer 15,38 
motor deficits  degree of motor weakness 4 or 6-point scale, examination  32,66 
? stiffness in fingers questionnaire 41,42 
loss of motion   stiffness during day 4-point scale on palpation or complaints 27,29 
functio laesa limited active ROM observation/examination  31 
inflammatory symptom limited active or passive ROM shoulder observation/examination  35 
motor function painless passive ROM shoulder 4-point scale with goniometer 66 
motor function passive ROM shoulder, wrist and MCP  goniometer 26 
contracture  ROM PIP joint, severity compared to other side 4-point scale 29 
joint function ROM shoulder, elbow and finger clinical assessment and goniometry 39 
joint mobility ROM fingers   goniometry 37 
loss of mobility ROM compared to other side 4-point mobility scale 9 
stiffness ROM all finger joints compared to other side goniometer 38 
loss of motion  ROM digital joints compared to other side goniometer 27,28 
motor function limitation ROM fingers when making fist compared to other side measurement tape  15,40 
motor function limitation ROM thumb 6-point scale 15,40 
motor function limitation active ROM shoulder+elbow+wrist compared to ROM normal ADL goniometer 15 
? active ROM compared to other side measurement tape and goniometer 10 
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(table 6) 
    
    
Concept Operationalisation Instrument(s) Reference No. 
  
Disability  
activity level rating of restriction of activities of daily living related to full-time job (100%) 11-point scale 32 
status of daily activities improvement in certain daily activities interview 3rd party  32 
daily activities difficulties with using hands last 24 hrs (in upper extremity CRPS) Visual Analog Scale (VAS) All Daily Activities 40 
hand function among others: restriction of everyday activities + performing simple tasks de Bruijn (1987) scoring system 42 
vocational or educational status changes in vocational or educational status compared to premorbid level questionnaire 68 
work status ? ability to perform occupational activity or ADL after 8 weeks of treatment analysis/interview 9 
employment status changes in job and/or working time compared to prior CRPS  questionnaire, interview 27 
occupational status long-term changes in occupation structured interview, 4 categories 45 
  
Handicap  
functional social activity level subjective grade of ability to return to premorbid levels questionnaire 68 
general health status  9 subscales (e.g. social functioning, role limitation, pain, mental health)  RAND-36 Questionnaire 45 
  
 
